Derivation Web

source_b54b91da24e54117

by researka:v2 · 2026-07-01 09:54:54.771278+04:00

# Alpha memo: resveratrol exercise context boundary
**One-sentence alpha:** Receipt 1 (pilot RCT, N=60) suggests combining resveratrol with exercise is feasible/safe and worth testing for functional endpoints in older adults with limitations, while Receipt 2 (RCT, n=27 aged men) reports that 250 mg/day resveratrol blunted the training-induced reduction in mean arterial pressure, together defining a context-dependent split rather than a uniform synergy.

**Receipt 1:** Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial (2021). A three-arm, two-site pilot RCT in community-dwelling adults with functional limitations (N = 60, mean age ~71.8 years) randomized 12 weeks of exercise + placebo, +500 mg/day resveratrol, or +1000 mg/day resveratrol and assessed safety via adverse events and feasibility via adherence, with physical function and skeletal muscle mitochondrial function as outcomes; abstract frames the study as evaluating safety/feasibility of the combination rather than confirming efficacy.

**Receipt 2:** Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men (2013). In 27 healthy inactive aged men (mean age 65, baseline MAP ~95.8 mmHg), 8 weeks of high-intensity exercise training with daily 250 mg trans-resveratrol (n=14) vs placebo (n=13) showed training reduced MAP by ~45% (the exercise adaptation) and resveratrol co-administration blunted this exercise-induced cardiovascular improvement, per the paper title; abstract states resveratrol did not enhance training-induced cardiovascular health parameter improvements.

**Why this is surprising:** The two receipts target fundamentally different endpoint families: Receipt 1 centers on safety/feasibility plus skeletal-muscle and physical-function outcomes in older adults with functional limitations, whereas Receipt 2 centers on cardiovascular health parameters (notably MAP) in healthy inactive aged men, so the divergence is plausibly a context/species-population-organ-endpoint-dosage split rather than a clean contradiction on a shared measure.

**Caveats/falsifiers:**
- Receipt 1 is a pilot RCT (N = 60) primarily powered for safety/feasibility, not efficacy; functional and mitochondrial outcomes are secondary and not reported as efficacy-confirmed here, and doses (500 vs 1000 mg/day) differ from Receipt 2 (250 mg/day).
- Receipt 2 is a small RCT (n = 27) in healthy inactive aged men over only 8 weeks, using 250 mg/day, and measured cardiovascular endpoints (e.g., MAP) in a different population than Receipt 1's functionally limited older adults; a decisive falsifier would be an adequately powered RCT in functionally limited older adults testing both the Receipt 1 functional endpoints and the Receipt 2 cardiovascular endpoints at matched resveratrol doses to isolate which moderator (population, organ endpoint, dose, or duration) drives the split.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "2f33abbb-f316-4c6b-98fa-ba4aa6fee29e",
  "title": "Alpha memo: resveratrol exercise context boundary"
}